Drug Profile
Research programme: biosimilars - AvesthaGen
Alternative Names: AVCADE™; AVCEPTIN™; AVCET™; AVEBEV™; AVETUX™; AVPLASE™Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Avesthagen
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in India (Parenteral)